Polymorphisms of glutathione S-transferase genes and survival of resected hepatocellular carcinoma patients

Table 4 Stratified analysis on the association between GSTO2: rs7085725 and GSTP1: rs4147581 genotype and overall survival of hepatocellular carcinoma patients

Variable	GSTO2: rs7085725				GSTP1: rs4147581
	Dead/Alive		HR (95%CI)	P value	Dead/Alive		HR (95%CI)	P value
	WW	WV + VV			WW	WV + VV
Age (yr)
≤ 55	32/52	19/5	1.86a (1.02-3.38)	0.044a	28/25	23/32	0.52a (0.30-0.92)	0.024a
> 55	49/43	11/3	1.71 (0.89-3.31)	0.110	29/21	31/25	0.92 (0.55-1.54)	0.755
Gender
Male	62/83	26/5	1.83a (1.14-2.94)	0.013a	44/38	44/50	0.64a (0.42-0.99)	0.042a
Female	19/12	4/3	0.76 (0.22-2.64)	0.663	13/8	10/7	1.06 (0.45-2.50)	0.902
Smoking behavior
No	52/67	19/6	1.35 (0.78-2.37)	0.287	35/26	36/47	0.58a (0.36-0.93)	0.024a
Yes	29/28	11/2	2.59a (1.27-5.27)	0.009a	22/20	18/10	1.06 (0.56-1.99)	0.870
Cirrhosis
Absent	41/30	12/5	1.21 (0.62-2.35)	0.579	23/17	30/18	0.91 (0.52-1.59)	0.746
Present	40/65	18/3	2.00a (1.11-3.59)	0.020a	34/29	24/39	0.50a (0.29-0.85)	0.011a
Child-Pugh score
A	61/87	17/7	2.28a (1.32-3.93)	0.003a	39/44	39/50	0.83 (0.53-1.30)	0.422
B	20/8	13/1	0.97 (0.47-2.03)	0.940	18/2	15/7	0.45a (0.22-0.90)	0.024a
AFP level (ng/mL)
< 200	39/40	14/7	1.09 (0.57-2.11)	0.793	26/17	27/30	0.51a (0.29-0.89)	0.018a
≥ 200	42/55	16/1	2.40a (1.34-4.29)	0.003a	31/29	27/27	0.85 (0.51-1.44)	0.552
Tumor size
< 5 cm	37/50	10/5	1.51 (0.74-3.06)	0.254	23/26	24/29	0.77 (0.43-1.38)	0.379
≥ 5 cm	44/45	20/3	1.59 (0.90-2.80)	0.109	34/20	30/28	0.60a (0.37-1.00)	0.048
TNM stage
I + II	44/60	11/4	1.24 (0.61-2.53)	0.555	27/26	28/38	0.64 (0.37-1.10)	0.104
III	37/35	19/4	1.66 (0.94-2.93)	0.081	30/20	26/19	0.75 (0.43-1.30)	0.311

^aP < 0.05 was considered statistically significant. WW: Homozygous wild-type genotype; WV: Heterozygous genotype; VV: Homozygous variant genotype.